Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)
Latest Information Update: 14 Sep 2022
At a glance
- Drugs Imgatuzumab (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms I-PACE
- Sponsors PegaOne
- 12 Sep 2022 Status changed from suspended to withdrawn prior to enrolment.
- 17 May 2022 Status changed from recruiting to suspended.
- 27 Jan 2022 Status changed from not yet recruiting to recruiting.